Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Review

(2782) Views  (931) Full article downloads

Authors: Jia Li, Muhammad Wasif Saif

Published Date September 2009 Volume 2009:3 Pages 429 - 441

DOI: http://dx.doi.org/10.2147/BTT.S5874

Jia Li, Muhammad Wasif Saif

Yale Cancer Center, Yale School of Medicine, New Haven CT, USA

Abstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

Keywords: advanced colon cancer, angiogenesis, bevacizumab, chemotherapy, metastatic, targeted therapy, vascular endothelial growth factor, gastric cancer, pancreatic cancer, hepatocellular cancer

Other articles by Dr Wasif Saif